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BACKGROUND
I had been training in India when I received a Rhodes Scholarship to go to 
Oxford. My interest as a medical student was in cardiology and at Oxford 
my initial goal was to work in pediatric cardiology. However, the pediatric 
cardiologist with whom I had corresponded fell ill and I had to go into 
another field. In the end, I worked with Professor Peter Sleight and Professor 
Richard Peto studying how beta-blockers reduced infarct size and acute 
infarction and saved lives. We did a series of studies that started with how 
to measure infarct size in people and how to administer the beta-blockers 
and their impact on different measures of infarct sizes and then ultimately 
the large First International Study of Infarct Survival (ISIS 1) with 16,000 
people that looked at beta-blockers saving lives in acute infarction.1 That 
then got me heavily into large-scale clinical trials and we were the first 
group that did meta-analysis in clinical medicine; these two tools, taking 
about ten years of work, got me started. 
I then did my clinical training in cardiology after which I went to the 
National Institutes of Health (NIH) in Bethesda, MD. There I had the 
opportunity to cover the World’s first major program in heart failure, which 
was called the Studies of Left Ventricular Dysfunction (SOLVD).2 I used 
my knowledge in acute infarction as well as cardiology to help the NIH set 
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up this major program and it became a landmark program that then set the 
stage for a series of studies using the same approach in heart failure. These 
studies were shown to save lives, prevent heart failure and prevent hospital-
ization and it is now standard therapy in medical practice.
During this time period, I got a much broader view of cardiovascular 
research because the NIH is such a fantastic place. So much is happening 
and they have so many top-notch people coming through that it is almost 
like a focal point where ideas are boiling. It was a great experience and I 
helped design other studies in atherosclerosis preventing arrhythmias and 
saw my colleagues work in hypertension and in cholesterol lowering. As a 
result, I got a very broad exposure to the important issues in research at 
NIH while at the same time focusing on a few ideas of my own. 
GLOBAL PROGRAMS
In 1992, I came to Canada and joined McMaster University as head of 
cardiology where we started up a couple of programs that are now in 84 
countries and that is about the time that I started to get a feel for global 
health. Previously, two or three years before I left NIH, I developed an 
interest in why south Asians develop premature heart disease as work I 
began with colleagues in India, Dr. Pais and others.3 Gradually we chipped 
away at that problem and it was the origins of the global study called 
INTERHEART that was done in 52 countries.4 That study looked at the 
causes of heart attacks and we were surprised to find that nine simple risk 
factors could account for most of the risk of heart attacks and that it was the 
same risk factors that mattered in people around the world. Today both 
findings are accepted as given but 15 years ago people did not think that way. 
This made prevention very easy; you just have essentially similar types of 
preventions globally but customized to local economic and cultural settings. 
We  have  followed  the  INTERHEART  study  with  an  ongoing  large 
study on stroke (INTERSTROKE) that now has about 20,000 people and 
about 40 countries involved.5 In the coming year, we will finish the study 
with approximately 25,000 people, looking at the causes of stroke world-
wide.  However,  a  stroke  is  much  more  complicated  than  heart  attacks 
because stroke is a heterogeneous condition. It involves hemorrhagic and 
ischemic stroke and even within each broad category ischemic strokes have 
different kinds of strokes and hemorrhagic strokes have different kinds of 
hemorrhagic strokes. Consequently, you require a lot of people with each 
kind of stroke to understand it; INTERSTOKE will provide great insights 
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Around the same time we also set up the large Prospective Urban Rural 
Epidemiology  (PURE)  Study,  which  has  about  400,000  people  in  17 
countries and about 620 communities. We are looking at how a changing 
environment, especially societal contrasts, had an impact on health habits 
and risk factors for cardiovascular disease.6 Out of the 400,000 people, 
about 156,000 adults are being followed long term. We are just finishing 
five-year follow up with many papers being written right now. 
In  my  work  we  have  also  gone  from  detecting  risk  factors  to  work 
involving modification of risk factors to see if that is able to prevent heart 
attacks and strokes. We have had a series of studies on cholesterol lowering, 
different  forms  of  blood  pressure  lowering  like  the  Heart  Outcomes 
Prevention  Evaluation  (HOPE)  Study,  testing  vitamins,  which  we  have 
shown repeatedly are pretty useless and testing a number of other hypotheses.7,8 
In addition, we have moved into other fields like atrial fibrillation and heart 
failure and various others. Thus, we have an active program globally on 
understanding the causes of heart disease but also how to modify it.
 More recently, about three years back, we started a program on what is 
called knowledge translation, which is implementation. It follows naturally; 
if you look at the impact of the trials that we have, the clinical utilization of 
our findings from research is relatively modest and slow. We now are trying 
to find why that is the case, how we can speed it up and how research 
findings can be translated into medical practice faster. Some people call it 
implementation science some call it knowledge translation; we deal with 
the whole range of it. 
Also in the last five years, in order to understand the causation of heart 
disease and stroke, we have started to look into understanding genetic and 
environmental components and how they interact. We have published a 
handful of papers so far, but really the program is now swinging and I think 
that will publish quite a lot of interesting findings. 
We are now moving into other forms of heart disease; what I call orphan 
diseases  like  Chagas  disease  in  South America.  Chagas  disease  affects 
about eight to ten million people with no known treatments for it because 
nobody  has  done  any  proper  evaluation  of  the  stages  of  the  disease 
progression. We are running the World’s largest study evaluating treatments 
in Chagas disease with 2700 people enrolled and about a four-year or five-
year follow up and we will get the result of that in about a year. We have 
another ongoing study on TB pericarditis in Africa; another orphan condition 
for which nothing has been clearly proven to be effective. In this case we are 
looking at treatment with steroids as well as a new vaccine. You can start to 
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or North Americans, but rather poor people around the world and there are 
a range of methodologies and a range of studies underway. Right now we 
are running about 35 medium- to large-scale studies.
THE POPULATION HEALTH RESEARCH INSTITUTE
The  Population  Health  Research  Institute  was  originally  known  as  the 
Preventive Cardiology and Therapeutics Research Program when it was 
first created some 20 years ago. About ten years back it grew and we called 
ourselves the Population Health Research Institute. It is a group that I 
founded and head up and it has about 250 researchers in research teams, 
large by Canadian standards and we are making a fair impact. We have 
about 30 investigators; they are a very dynamic, committed and motivated 
set of people. 
We  link  with  people  in  diabetes,  kidney  disease,  stroke,  infectious 
diseases, health policy, and knowledge translation. Recently, we began 
collaborations with the engineering department to look at issues of water 
safety, environment and health. We are collaborating with experts in gastro-
intestinal diseases because there is a theory that microbes or what is called 
the microbiome has an effect on modulating obesity. So there is a lot of 
lateral thinking in our group, a lot of external collaboration and we work on 
a range of research around the world. 
I think our key strength is our ability to absorb other people’s ideas and 
collaborate;  that  is  how  we  grow.  We  have  about  20  scientists  who 
collaborate with us closely that are not based at Hamilton, Canada but 
come for one or two weeks per year and work and communicate with us 
through long distance e-mails the remainder of the time. There are people 
in about 50 different countries with whom we have collaborated with in 
study after study and who helped us set up our networks. So the Institute is 
fairly universal not in terms of geography alone but in the broad way we 
think. We do not work in silos; we collaborate between groups within the 
Institute and across with other groups at other universities. That has been 
our strength. We learn from other people all the time. 
CHALLENGES AND BENEFITS OF WORKING GLOBALLY
There are obviously challenges to working on a global scale. The biggest 
challenge is raising enough money because it is difficult to find money for 
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usually  the  country  you  live  in. The  second  challenge  is  obviously  the 
regulatory, contractual bureaucracy that we have to deal with. It is a huge job, 
but we learned how to deal with it and we employ people with expertise in it. 
However,  the  benefits  are  that  you  are  doing  work  that  has  global 
applicability. You  are  influencing  health  and  related  policy  worldwide. 
These studies have global impact and ultimately it is very satisfying because 
you are working with highly selected people who are incredibly motivated 
around the world—in India, China, Africa or South America working with 
us, these are people who do not have to do it. They are paid a very little , 
but we just enjoy the collaboration and the opportunities. These are some 
of the finest people both in terms of intellect and heart with what they really 
want to do and their priorities. Participating internationally is one of the 
most humiliating and gratifying parts of my work because the enthusiasm 
for the questions people ask is so much oriented towards the right thing: 
How do we solve a major problem? 
For almost all our studies the funding we get does not cover the cost of 
doing the work, not even half the cost and our collaborators worldwide 
scrape together funds to supplement what we provide. So on one hand there 
is a challenge and on another hand there is an opportunity. It is hand to 
mouth, but we have managed to keep many of our global studies going now 
for 20 years so hopefully it will keep on going for a longer time. 
TRANSLATION FROM SCIENCE INTO PRACTICE
We have had a number of results that have been accepted and gradually 
incorporated into practice. The issue is not that we do not see translation of 
our results, it is a matter of to what degree do you have an impact and how 
broad is the impact. For instance, we were one of the groups that showed 
that ACE inhibitors saved lives and prevented heart attacks and strokes in 
people with and without heart failure and irrespective of any other criteria. 
Our results have been accepted worldwide, they are in every guideline for 
secondary  prevention  and  have  been  approved  by  regulators  in  many 
countries around the world. But, if you look at the use of these drugs after 
a heart attack, usage is initially high to prevent heart failure after somebody 
who has come to the hospital. Then, if you look at the group of people with 
the same condition five years out from an event, there is a drop off in use of 
these treatments, which need to be taken for life. Globally only ten to 20 
percent of people are receiving treatment. Even in wealthy countries like 
Canada only about 25 to 30 percent are receiving it and in poor countries it 
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The  gap  in  treatment  usually  happens  when  people  stop  getting  in 
contact with the health care system. This is even the case with simple 
aspirin; if you take a country like India or China only five to ten percent of 
people after a heart attack or stroke are receiving aspirin long-term. I think 
the issues are related to a lack of knowledge and a lack of a system. There 
is no system to ensure long-term care and there are costs associated with 
going to see health practitioners. If you have to go and see a doctor to get 
your aspirin renewed, the cost of going to see the doctor is many times the 
cost of aspirin. 
We need new systems in place, so we are working with a group of 
people to propose community projects to try to overcome the barriers in the 
system. The systemic barriers are the ones that we need to deal with. For 
common conditions having a physician centric approach is not going to 
work; there are not enough physicians and even the cheapest physician is 
far too expensive to deal with an epidemic. One of our goals is to promote 
the concept of health shifting. Some of the simple things physicians are 
doing can be given to less highly trained people and what they are doing is 
shifted down so everything will ratchet down a notch. Hopefully with this 
approach you can improve access and decrease cost and therefore you 
increase impact. Therefore, a lot of our current work is on how do we take 
current knowledge and make sure it is utilized to a greater extent on a 
sustained basis in practice. 
OVERCOMING DIFFICULTIES IN RESOURCE CHALLENGED 
SETTINGS
As discussed before, funds are the main challenge to implementing work in 
resource challenged locations, another is finding the qualified personnel. 
Although, we have found that because our studies are very simple, even in 
sub Saharan Africa or in rural Sudan, we can find people who can carry out 
our protocols very well. Obviously quality control is a big issue, supervision 
is a big issue and I think the key thing in all of this is personal contact. We 
have strong personal relationships with key people in each country, who in 
turn have strong personal relationships with key investigators in different 
parts of the country, who in their turn have good relationship with people at 
the grassroots level. A chain of good relationships is key and it can overcome 
a lot of problems. 
A third difficulty is the logistics of what we do and by and large we have 
been able to overcome this by having innovative means of blood collection, 
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Bureaucracy  becomes  another  big  challenge  as  many  developing 
countries are putting up new barriers to international collaborations, partly 
because some people from the West have abused their privileges and have 
done studies that may be unethical or even if ethical, they did not get the 
right approvals. This then raises concerns ; walls get put up and what would 
normally take one month to start a study now takes a year or two to get the 
approvals. Increasing bureaucracy and regulations in different countries is 
a major challenge. 
And the other challenge is finding enough young motivated people to 
go into serious health research and the point is the word “serious”. Because 
to become a good health researcher you must throw yourself in for ten 
years before you can even say you have the chance to become a good 
researcher. That is a long slog after someone has done their medical school 
and residency. Essentially you are telling them they have done ten years of 
training in medical school and residency and now here is ten more years of 
training. Very few people are made out for it and that is perfectly OK, in the 
end we do it because the benefits outweigh the challenges and it is a fun 
thing to do. One of my biggest satisfactions is training people, helping 
them grow and seeing them succeed. 
ENCOURAGING YOUNG PEOPLE IN HEALTH RESEARCH
I think the key thing when we look to encourage young people to go into 
health research is that we cannot influence the innate sense of altruism that 
some people have and others do not. But, let’s say we take somebody who 
has a fair modicum of it, a fair degree of intelligence, a fair degree of 
curiosity and a willingness to come and work with people on important 
questions; what I can do is create an environment in which we can promote 
their success. We have dealt with quite a few people this way and usually 
when they see they are benefiting and helping other people then you create 
a virtuous chain reaction. One generation helps the next and that generation 
helps the one to follow it. 
Not everybody who is helped will help others but there are enough 
people  who  will  do  it.  I  benefited  enormously  from  my  mentors  and 
professors; Professors Peter Sleight and Richard Peto, my colleague Rory 
Collins with whom I collaborated while I was at Oxford, and several people 
who helped me when I was at NIH. It is personal example in inspiring 
people that this is a wonderful way to live one’s life and with the field that I 
am in, I can see the benefits to people, to patients and to the public. You can 
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what I am dong and I think many of the people around me share that feeling. 
We do not need a large number of people doing any kind of research, what 
you want is people who are very committed and motivated and who work 
on a sustained basis. I really think that most physicians should really just be 
good doctors and look after patients; that is what we are there for. And a few 
committed and excellent people going into health research is a good idea. 
FUTURE GOALS AND DIRECTIONS FOR RESEARCH
I always have future directions for research for the next five or ten years, 
but they keep on changing. I will continue with my global health work 
because that is what I am passionate about, but increasingly I am looking 
into new interfaces. For instance knowledge translation, we now have a 
number of projects in this area and some of my recent grants have had a 
large emphasis on that. Another part is looking at the legal and social issues 
and how they effect the implementation of our programs. A third one is 
working with engineers and biologists in developing point of care devices 
to  diagnose  at  low  cost  in  remote  settings.  I  also  find  it  intellectually 
stimulating to collaborate with my colleagues who are working in genetics. 
Although I have reservations on how much it will improve human health at 
least in CVD and in the next decade, genetics can provide useful and novel 
insights into biology if done intelligently. I continue to work on strokes and 
diabetes and obesity. I continue to lead a few studies, but increasingly I help 
younger  people  set  up  major  studies  and  provide  advice,  support  and 
sometimes financing to help them get started in the form of seed money. So 
my role has evolved to creating structures and an environment where others 
can succeed. It is a role I enjoy while I continue to do research. 
ADVICE TO YOUNG RESEARCHERS 
I think that my advice to those entering the field is to have a dream and to 
focus on it. Do not try to have too many dreams because then you cannot 
achieve anything. Identify a team of people or an individual that you can 
relate to that works in your field of interest and take a question and work 
through it systematically. I often find young people trying to be involved in 
eight or ten projects and they feel very proud that they are very busy, but 
that usually means they are not achieving much in anything. I usually tell 
young people take one project, focus and run with it and once you are really 
smart and have learned a lot then you can do a little bit of diversification. Preface:SalimYusuf 371
Do not do what I am doing now (i.e., working in many projects), stay very 
focused as I did during the first decade and half of my career.
I also warn them that this is a long haul; to make progress on any 
important question takes many years. We will help them, but they themselves 
need to be ready to commit to the long haul. 
My role is in nurturing them so that they succeed; in health research you 
have more failures than successes. So I try to be a counselor, helping tide 
young people through rejections of grants and papers. Despite these types 
of setbacks, the work is important and we can find another way to get 
something done. We have grants that were funded on the sixth attempt and 
because it was important we persisted. So we teach young people persistence. 
My advice to young people is to think of one or two important questions, 
but  do  not  think  of  small  questions  or  forty  questions.  Focus  on  one 
important question, and devote the next several years of your life trying to 
make advancements there. And people must do this with their eyes open. 
Research is a reasonable living, nobody is going to be poor, but people need 
to understand, for a physician especially, you are going to make less than 
your colleagues who are in clinical practices. That is a choice one voluntarily 
makes. Most people accept it and they know they are having fun.
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